Does OSIMERTINIB Cause Salivary hypersecretion? 8 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Salivary hypersecretion have been filed in association with OSIMERTINIB (TAGRISSO). This represents 0.0% of all adverse event reports for OSIMERTINIB.
8
Reports of Salivary hypersecretion with OSIMERTINIB
0.0%
of all OSIMERTINIB reports
0
Deaths
1
Hospitalizations
How Dangerous Is Salivary hypersecretion From OSIMERTINIB?
Of the 8 reports, 1 (12.5%) required hospitalization.
Is Salivary hypersecretion Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OSIMERTINIB. However, 8 reports have been filed with the FAERS database.
What Other Side Effects Does OSIMERTINIB Cause?
Death (10,423)
Malignant neoplasm progression (2,920)
Diarrhoea (1,408)
Drug resistance (1,026)
Fatigue (819)
Rash (772)
Decreased appetite (706)
Drug ineffective (627)
Dyspnoea (621)
Nausea (610)
What Other Drugs Cause Salivary hypersecretion?
CLOZAPINE (1,349)
ARIPIPRAZOLE (497)
RISPERIDONE (485)
OLANZAPINE (449)
QUETIAPINE (299)
CARBIDOPA\LEVODOPA (248)
HALOPERIDOL (216)
DIAZEPAM (185)
CLONAZEPAM (179)
LORAZEPAM (165)
Which OSIMERTINIB Alternatives Have Lower Salivary hypersecretion Risk?
OSIMERTINIB vs OSPEMIFENE
OSIMERTINIB vs OSPHENA
OSIMERTINIB vs OVINE DIGOXIN IMMUNE FAB
OSIMERTINIB vs OXACILLIN
OSIMERTINIB vs OXALIPLATIN